Research labs were closed, men had their treatments delayed, and much of our activity grinded to a halt, but prostate cancer didn’t, so neither did we.
New data shows prostate cancer is the most common cancer in the UK. Here's why it's not all bad news, and what we do next.
News of a new prostate cancer test hit the headlines yesterday. It’s a promising step forward in improving diagnosis, but is there enough research to show the test could be accurate enough to end the need for biopsy?
Promising new research finds a chemical signature in urine that can predict the presence and aggressiveness of prostate cancer. However, more tests are needed to compare it against new MRI scans.
Allowing men to access test results online provides just as good support while saving the NHS money.
The environmental journalist and activist is the latest high-profile man to open up about having prostate cancer, after writing a searingly honest column giving his three top tips for keeping upbeat in the face of the disease.
After an operation successfully got rid of his prostate cancer in 2012, Steve Ellis set about warning his eight brothers of their increased risk of the disease, encouraging them to get tested. He tells us about their mixed reactions and how three have now also been diagnosed.
A new report from the medical professionals' body includes the PSA test as one of 40 medical treatments that may be unnecessary for many men. But Prostate Cancer UK makes clear that the test is still the best first step for diagnosis of prostate cancer while we develop a more robust test suitable for a screening programme.
We know that having tests for prostate cancer can be stressful and worrying. That's why, with the help of volunteers like Phil Watson, we’ve updated our fact sheet: How prostate cancer is diagnosed. He talks to us about his own diagnosis with prostate cancer in 2011, aged 61, and the experiences he had of having a range of tests before treatment.
BLOG: Following a report in the Mirror yesterday of a massive rise in diagnosis of advanced prostate cancer in the United States and a call for more PSA screening there, our resident expert Dr Sophie Lutter cautions against such an approach here.